title: A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis.
abstract: BACKGROUND
  The capacity of sublingual allergen immunotherapy (SLIT) to provide effective symptom relief in pollen-induced seasonal allergic rhinitis is often questioned, despite evidence of clinical efficacy from meta-analyses and well-powered, double-blind, placebo-controlled randomized clinical trials. In the absence of direct, head-to-head, comparative trials of SLIT and symptomatic medication, only indirect comparisons are possible.
  
  
  METHODS
  We performed a meta-analysis of classes of products (second-generation H1-antihistamines, nasal corticosteroids and grass pollen SLIT tablet formulations) and single products (the azelastine-fluticasone combination MP29-02, and the leukotriene receptor antagonist montelukast) for the treatment of seasonal allergic rhinitis in adults, adolescents and/or children. We searched the literature for large (n >100 in the smallest treatment arm) double-blind, placebo-controlled randomized clinical trials. For each drug or drug class, we performed a meta-analysis of the effect on symptom scores. For each selected trial, we calculated the relative clinical impact (according to a previously published method) on the basis of the reported post-treatment or season-long nasal or total symptom scores: 100 × (scorePlacebo - scoreActive)/scorePlacebo.
  
  
  RESULTS
  Twenty-eight publications on symptomatic medication trials and ten on SLIT trials met our selection criteria (total number of patients: n = 21,223). The Hedges' g values from the meta-analyses confirmed the presence of a treatment effect for all drug classes. In an indirect comparison, the weighted mean (range) relative clinical impacts were -29.6% (-23% to -37%) for five-grass pollen SLIT tablets, -19.2% (-6% to -29%) for timothy pollen SLIT tablets, -23.5% (-7% to -54%) for nasal corticosteroids, -17.1% (-15% to -20%) for MP29-02, -15.0% (-3% to -26%) for H1-antihistamines and -6.5% (-3% to -10%) for montelukast.
  
  
  CONCLUSIONS
  In an indirect comparison, grass pollen SLIT tablets had a greater mean relative clinical impact than second-generation antihistamines and montelukast and much the same mean relative clinical impact as nasal corticosteroids. This result was obtained despite the presence of methodological factors that mask the clinical efficacy of SLIT for the treatment of seasonal allergic rhinitis.
authors.affiliation: UPRES EA 220 & Clinical Research Department, Foch Hospital, University of Versailles Saint-Quentin, Suresnes, France. p.devillier@hopital-foch.org.
authors.forename: Philippe
authors.initials: P
authors.lastname: Devillier
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Dreyfus
authors.forename: Pascal
authors.initials: P
authors.lastname: Demoly
authors.forename: Moisés A
authors.initials: MA
authors.lastname: Calderón
mesh_terms: D000085:Acetates / Q000008:administration & dosage; D000286:Administration, Sublingual; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000328:Adult; D000485:Allergens / Q000008:administration & dosage* / Q000276:immunology; D000730:Androstadienes; D002648:Child; D003233:Conjunctivitis, Allergic / Q000276:immunology / Q000628:therapy*; D003521:Cyclopropanes; D003888:Desensitization, Immunologic / Q000379:methods; D004311:Double-Blind Method; D004338:Drug Combinations; D039563:Histamine H1 Antagonists, Non-Sedating / Q000008:administration & dosage; D006801:Humans; D020024:Leukotriene Antagonists / Q000008:administration & dosage; D010793:Phthalazines; D011058:Pollen / Q000276:immunology; D011804:Quinolines / Q000008:administration & dosage; D006255:Rhinitis, Allergic, Seasonal / Q000276:immunology / Q000628:therapy*; D012621:Seasons; D063729:Sublingual Immunotherapy; D013440:Sulfides
chemical_list: D000085:Acetates; D000305:Adrenal Cortex Hormones; D000485:Allergens; D000730:Androstadienes; D003521:Cyclopropanes; D004338:Drug Combinations; D039563:Histamine H1 Antagonists, Non-Sedating; D020024:Leukotriene Antagonists; C573864:MP29-02; D010793:Phthalazines; D011804:Quinolines; D013440:Sulfides; C093875:montelukast